These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

405 related articles for article (PubMed ID: 31439577)

  • 1. Chimeric Antigen Receptor T Cells Targeting CD79b Show Efficacy in Lymphoma with or without Cotargeting CD19.
    Ormhøj M; Scarfò I; Cabral ML; Bailey SR; Lorrey SJ; Bouffard AA; Castano AP; Larson RC; Riley LS; Schmidts A; Choi BD; Andersen RS; Cédile O; Nyvold CG; Christensen JH; Gjerstorff MF; Ditzel HJ; Weinstock DM; Barington T; Frigault MJ; Maus MV
    Clin Cancer Res; 2019 Dec; 25(23):7046-7057. PubMed ID: 31439577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chimeric antigen receptor T cells to target CD79b in B-cell lymphomas.
    Chu F; Cao J; Liu J; Yang H; Davis TJ; Kuang SQ; Cheng X; Zhang Z; Karri S; Vien LT; Bover L; Sun R; Vega F; Green M; Davis RE; Neelapu SS
    J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 38007239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical Assessment of Efficacy and Safety Analysis of CAR-T Cells (ISIKOK-19) Targeting CD19-Expressing B-Cells for the First Turkish Academic Clinical Trial with Relapsed/Refractory ALL and NHL Patients.
    Taştan C; Kançağı DD; Turan RD; Yurtsever B; Çakırsoy D; Abanuz S; Yılancı M; Seyis U; Özer S; Mert S; Kayhan CK; Tokat F; Açıkel Elmas M; Birdoğan S; Arbak S; Yalçın K; Sezgin A; Kızılkılıç E; Hemşinlioğlu C; İnce Ü; Ratip S; Ovalı E
    Turk J Haematol; 2020 Nov; 37(4):234-247. PubMed ID: 32755128
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD19-specific CAR T Cells that Express a PD-1/CD28 Chimeric Switch-Receptor are Effective in Patients with PD-L1-positive B-Cell Lymphoma.
    Liu H; Lei W; Zhang C; Yang C; Wei J; Guo Q; Guo X; Chen Z; Lu Y; Young KH; Lu Z; Qian W
    Clin Cancer Res; 2021 Jan; 27(2):473-484. PubMed ID: 33028589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a compact bidirectional promoter-driven dual chimeric antigen receptor (CAR) construct targeting CD19 and CD20 in the Sleeping Beauty (SB) transposon system.
    Khaniya A; Rad SMAH; Halpin J; Tawinwung S; McLellan A; Suppipat K; Hirankarn N
    J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38677881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of novel humanized CD19/BAFFR bicistronic chimeric antigen receptor T cells with potent antitumor activity against B-cell lineage neoplasms.
    Wu S; Luo Q; Li F; Zhang S; Zhang C; Liu J; Shao B; Hong Y; Tan T; Dong X; Chen B
    Br J Haematol; 2024 Oct; 205(4):1361-1373. PubMed ID: 38960449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T cells redirected against Igβ for the immunotherapy of B cell lymphoma.
    Jiang D; Tian X; Bian X; Zhu T; Qin H; Zhang R; Xu Y; Pan Z; Huang H; Fu J; Wu D; Chu J
    Leukemia; 2020 Mar; 34(3):821-830. PubMed ID: 31624374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Construction of a new anti-CD19 chimeric antigen receptor and the anti-leukemia function study of the transduced T cells.
    An N; Tao Z; Li S; Xing H; Tang K; Tian Z; Rao Q; Wang M; Wang J
    Oncotarget; 2016 Mar; 7(9):10638-49. PubMed ID: 26840021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TGF-β/IL-7 Chimeric Switch Receptor-Expressing CAR-T Cells Inhibit Recurrence of CD19-Positive B Cell Lymphoma.
    Noh KE; Lee JH; Choi SY; Jung NC; Nam JH; Oh JS; Song JY; Seo HG; Wang Y; Lee HS; Lim DS
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-CD19 CAR T cells potently redirected to kill solid tumor cells.
    Ambrose C; Su L; Wu L; Dufort FJ; Sanford T; Birt A; Hackel BJ; Hombach A; Abken H; Lobb RR; Rennert PD
    PLoS One; 2021; 16(3):e0247701. PubMed ID: 33735268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor Potency of an Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, Lisocabtagene Maraleucel in Combination With Ibrutinib or Acalabrutinib.
    Qin JS; Johnstone TG; Baturevych A; Hause RJ; Ragan SP; Clouser CR; Jones JC; Ponce R; Krejsa CM; Salmon RA; Ports MO
    J Immunother; 2020 May; 43(4):107-120. PubMed ID: 31899702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Cerebroventricular Environment Modifies CAR T Cells for Potent Activity against Both Central Nervous System and Systemic Lymphoma.
    Wang X; Huynh C; Urak R; Weng L; Walter M; Lim L; Vyas V; Chang WC; Aguilar B; Brito A; Sarkissian A; Bandara NA; Yang L; Wang J; Wu X; Zhang J; Priceman SJ; Qin H; Kwak LW; Budde LE; Thomas SH; Clark MC; Popplewell L; Siddiqi T; Brown CE; Forman SJ
    Cancer Immunol Res; 2021 Jan; 9(1):75-88. PubMed ID: 33093217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of Nonviral
    Lin Z; Liu X; Liu T; Gao H; Wang S; Zhu X; Rong L; Cheng J; Cai Z; Xu F; Tan X; Lv L; Li Z; Sun Y; Qian Q
    Front Immunol; 2021; 12():802705. PubMed ID: 35082789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chimeric Antigen Receptor-Engineered T Cell Therapy in Lymphoma.
    Strati P; Neelapu SS
    Curr Oncol Rep; 2019 Mar; 21(5):38. PubMed ID: 30919158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ShRNA-mediated silencing of PD-1 augments the efficacy of chimeric antigen receptor T cells on subcutaneous prostate and leukemia xenograft.
    Zhou JE; Yu J; Wang Y; Wang H; Wang J; Wang Y; Yu L; Yan Z
    Biomed Pharmacother; 2021 May; 137():111339. PubMed ID: 33550044
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [CAR-T cells in lymphomas: Current and evolving role].
    Messéant O; Houot R
    Bull Cancer; 2021 Oct; 108(10S):S28-S39. PubMed ID: 34920805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transferrin epitope-CD19-CAR-T cells effectively kill lymphoma cells
    Valentine M; Li L; Zhou H; Xu S; Sun J; Liu C; Harto H; Berahovich R; Golubovskaya V; Wu L
    Front Biosci (Landmark Ed); 2020 Jan; 25(2):270-282. PubMed ID: 31585889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unraveling resistance mechanisms in anti-CD19 chimeric antigen receptor-T therapy for B-ALL: a novel in vitro model and insights into target antigen dynamics.
    Li H; Wang Y; Liu R; Li X; Zhang P; Chen P; Zhao N; Li B; Wang J; Tang Y
    J Transl Med; 2024 May; 22(1):482. PubMed ID: 38773607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic and persistent effect of T-cell immunotherapy with anti-CD19 or anti-CD38 chimeric receptor in conjunction with rituximab on B-cell non-Hodgkin lymphoma.
    Mihara K; Yanagihara K; Takigahira M; Kitanaka A; Imai C; Bhattacharyya J; Kubo T; Takei Y; Yasunaga S; Takihara Y; Kimura A
    Br J Haematol; 2010 Oct; 151(1):37-46. PubMed ID: 20678160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-CD19 CAR T-Cell Therapy for B-Cell Non-Hodgkin Lymphoma.
    Abramson JS
    Transfus Med Rev; 2020 Jan; 34(1):29-33. PubMed ID: 31677848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.